Resmetirom
Phase 3ActiveInterest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Fatty Liver Disease
Conditions
Non-Alcoholic Fatty Liver Disease
Trial Timeline
Jul 9, 2021 → Apr 1, 2026
NCT ID
NCT04951219About Resmetirom
Resmetirom is a phase 3 stage product being developed by Madrigal Pharmaceuticals for Non-Alcoholic Fatty Liver Disease. The current trial status is active. This product is registered under clinical trial identifier NCT04951219. Target conditions include Non-Alcoholic Fatty Liver Disease.
What happened to similar drugs?
0 of 3 similar drugs in Non-Alcoholic Fatty Liver Disease were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04951219 | Phase 3 | Active |
Competing Products
20 competing products in Non-Alcoholic Fatty Liver Disease